Somatostatin in the treatment of patients with extrapyramidal disorders and patients with EEG abnormalities

Publisher Website
Google Scholar
Abstract
The growth hormone release inhibiting hormone acts probably both as a true hypophysiotropic hormone and as a neuroregulatory substance. Neurophysiological studies have shown that somatostatin is a CNS depressant. Somatostatin might therefore be of therapeutic significance in neurological diseases. Sixteen patients with different extrapyramidal disorders and seven patients with various EEG abnormalities were tested with 2‐hour somatostatin infusions and control infusions with saline. Somatostatin did not induce any improvement or deterioration of symptoms, signs, or EEG abnormalities in any patient.